Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19FN2O7S |
| Molecular Weight | 401.397 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC[C@H](NC(=O)N[C@@H](CSCC1=CC=C([18F])C=C1)C(O)=O)C(O)=O
InChI
InChIKey=IDTMSHGCAZPVLC-STUNTBJNSA-N
InChI=1S/C16H19FN2O7S/c17-10-3-1-9(2-4-10)7-27-8-12(15(24)25)19-16(26)18-11(14(22)23)5-6-13(20)21/h1-4,11-12H,5-8H2,(H,20,21)(H,22,23)(H,24,25)(H2,18,19,26)/t11-,12-/m0/s1/i17-1
DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor-associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. F 18 DCFBC is investigated in phase 2 clinical trials in patients with prostate cancer.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TUP7882K8T
Created by
admin on Sat Dec 16 08:07:33 GMT 2023 , Edited by admin on Sat Dec 16 08:07:33 GMT 2023
|
PRIMARY | |||
|
1169942-33-9
Created by
admin on Sat Dec 16 08:07:33 GMT 2023 , Edited by admin on Sat Dec 16 08:07:33 GMT 2023
|
PRIMARY | |||
|
25067411
Created by
admin on Sat Dec 16 08:07:33 GMT 2023 , Edited by admin on Sat Dec 16 08:07:33 GMT 2023
|
PRIMARY | |||
|
DB14772
Created by
admin on Sat Dec 16 08:07:33 GMT 2023 , Edited by admin on Sat Dec 16 08:07:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
